Finnish research shows young people often remain on ADHD medication for years—well past available safety data.
A new study from the University of Turku, the University of Helsinki, and Finland’s Social Insurance Institution (Kela) has uncovered that children and adolescents with ADHD are staying on medication for an average of over three years. For many, treatment continues even longer. In fact, among the quarter of children with the longest treatment times, medication use lasted more than seven years.
While ADHD medication use has surged in recent years, especially among young people, the science around its long-term safety is still catching up. Currently, the most reliable clinical trials only track the safety of these medications for one year. This leaves a big question mark about what extended use means for growing children.
“This is an important research opening, as the duration of long-term use of ADHD medication in children and adolescents in everyday life has only been studied to a very limited extent,” says the study lead Päivi Ruokoniemi, a Specialist in both Clinical Pharmacology and Therapeutics and Child Psychiatry from the University of Helsinki.
Boys treated more often and for longer periods
The study found that both gender and the age at which ADHD medication is started have a significant effect on the duration of treatment. On average, ADHD treatment lasted just over a year longer for boys than for girls. For both genders, an early age of onset led to longer medication treatment.
The longest duration of ADHD medication was for boys who started medication at the age of 6–8 years. The median duration of their medication treatment was 6.3 years, and for a quarter of them the treatment lasted more than 9.4 years. This group was also the largest group to start ADHD medication. Boys aged 6 to 8 accounted for 32.4 percent of the study subjects.
“Our research shows that a significant proportion of young children, especially boys, are on ADHD medication for years, throughout their comprehensive school years. In this context, it is worrying that reliable research data on the safety of these medicines is only available for a follow-up period of up to one year. After all, we are talking about children at a very sensitive stage of development,” says Ruokoniemi.
Studies on long-term effects lacking
The most reliable evidence for the safety of medicines comes from clinical, controlled, and randomized trials. For the regulatory approval of ADHD medications, the European Medicines Agency requires pharmaceutical companies to establish clinical safety with a study covering at least one year of follow-up.
“The long-term effects of ADHD medicines have been studied extensively in various observational and uncontrolled research settings, but these are always prone to confounding and therefore do not provide reliable information on cause-and-effect relationships,” continues Ruokoniemi.
“Due to these uncertainties, it is important that ADHD medication is only started when non-pharmacological treatments have been deemed insufficient. Even in this case, it must be ensured that both the caregiver and the child, in accordance with the child’s age and level of development, have access to sufficient information on the expected benefits and harms of the medicine and the uncertainties associated with them.”
The researchers also recommend that the need for ADHD medication that has already been started should be reviewed annually by a medical doctor.
The descriptive register study, recently published in the journal European Child & Adolescent Psychiatry, was carried out as a research collaboration between the Universities of Turku and Helsinki and the Finnish Social Insurance Institution Kela. The data used in the study was from the register of dispensations reimbursable under the National Health Insurance Scheme for the years 2008–2019. The data included nearly 41,000 children and young people who had started medication treatment in Finland. The duration of medication treatment was estimated using Kaplan-Meier survival analysis.
In 2019, the last year of the study data, the prevalence of ADHD medication was 5–6 percent for boys and 1.3–1.5 percent for girls. Since then, the use of ADHD medication has continued to increase both globally and also in Finland, where the increase has been even faster than in other Nordic countries.
“We know that the proportion of Finnish children and adolescents using ADHD medication in Finland has already doubled since the years we conducted our research,” says Ruokoniemi.
Reference: “Duration of ADHD medication treatment among Finnish children and adolescents ‒ a nationwide register study” by Terhi A. Kolari, Miika Vuori, Hanna Rättö, Eveliina A. Varimo, Eeva T. Aronen, Kari Auranen, Leena K. Saastamoinen and Päivi T. Ruokoniemi, 7 May 2025, European Child & Adolescent Psychiatry.
DOI: 10.1007/s00787-025-02735-4
Never miss a breakthrough: Join the SciTechDaily newsletter.
